Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Clin Cancer Res. 2019 Apr 26;25(15):4712–4722. doi: 10.1158/1078-0432.CCR-19-0225

Figure 6. Study summary and clinical findings.

Figure 6.

RNASeq-based matched therapy for 10/33 patients whose tumors were found to be positive for gene fusions (9) or METex14 (1). 80% of the patients have shown clinical benefit. PR: partial response, SD: stable disease; PD: progression of disease. * Response assessment by RECIST v1.1. ** Confirmed PR